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ABSTRACT: Learning and memory deficits in Alzheimer’s disease (AD) result from synaptic failure and neuronal loss, the latter
caused in part by excitotoxicity and oxidative stress. A therapeutic approach is described that uses NO-chimeras directed at
restoration of both synaptic function and neuroprotection. 4-Methylthiazole (MZ) derivatives were synthesized, based upon a
lead neuroprotective pharmacophore acting in part by GABAA receptor potentiation. MZ derivatives were assayed for protection
of primary neurons against oxygen−glucose deprivation and excitotoxicity. Selected neuroprotective derivatives were
incorporated into NO-chimera prodrugs, coined nomethiazoles. To provide proof of concept for the nomethiazole drug class,
selected examples were assayed for restoration of synaptic function in hippocampal slices from AD-transgenic mice, reversal of
cognitive deficits, and brain bioavailability of the prodrug and its neuroprotective MZ metabolite. Taken together, the assay data
suggest that these chimeric nomethiazoles may be of use in treatment of multiple components of neurodegenerative disorders,
such as AD.
■ INTRODUCTION
Alzheimer’s disease (AD) is an age-related neurodegenerative
disease manifested by progressive memory loss, decline in
language skills, and other cognitive impairments. The disorder
is reaching epidemic proportions, with a large human, social,
and economic burden.1 Currently approved treatments may
temporarily reduce the rate of cognitive decline in a limited
number of patients, without halting disease progression;
however, no treatment is considered disease-modifying.2
Diverse factors play a role in the pathogenesis of AD, notably
abnormal aggregation of amyloid β (Aβ) and tau protein,
glutamate-induced excitotoxicity, oxidative stress, and inflam-
mation.3 Accordingly, a variety of therapeutic strategies
modulating the progression or prevention of AD are currently
being investigated.4,5 AD represents a major unmet medical
need.
Excitotoxicity is a mechanism of neuronal dysfunction and
cell death characterized by excessive stimulation of glutamate
receptors, pathological elevation of intracellular calcium
concentration, and mitochondrial damage. The methylthiazole
(MZ) containing GABA-mimetic agent clomethiazole (CMZ,
Scheme 1) potentiates the function of the inhibitory neuro-
transmitter GABA in the brain,6−8 attenuating glutamate
induced excitotoxicity. CMZ has seen clinical use in a number
of indications,9−11 and study of compounds related to CMZ has
shown that anticonvulsant and hypnotic potency could be
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dissociated and modulated separately.12−17 Under the name
Zendra, CMZ was explored in clinical trials including phase III
trials as a neuroprotective drug for use in spinal cord injury and
ischemic stroke,18−25 and CMZ continues to be suggested as a
potential component of future combination therapies for
neuronal injury.26 CMZ has also been demonstrated to
counteract inflammation, lowering levels of proinflammatory
cytokines, including TNFα,27,28 and to rescue mitochondrial
function in brain tissues.29 Recent evidence, from both clinical
observations and mouse model studies, supports TNFα as a
therapeutic target in AD.30−32 Likewise, restoration of
mictochondrial function is seen as a strategy for AD
therapy.33,34 Therefore, MZ derivatives, capable of eliciting
neuroprotection and attenuating neuroinflammation, are of
potential clinical utility in AD.
An early event in AD is synaptic failure.35 Restoration of
synaptic function via activation of cAMP-responsive element
binding factor (CREB) is seen as a new target for treatment of
AD and other neurological disorders.36−43 Activation of CREB
is known to enhance or restore long-term potentiation (LTP)
and the expression of corresponding gene products to enhance
neuronal plasticity and neurogenesis.44−46 Since activation of
CREB in the hippocampus is tightly coupled to NO/cGMP
signaling,44,46−49 restoration of normal NO/cGMP signaling in
the aging brain is essential to preserve both synaptic and
neuronal survival and function. NO-mimetic agents that
enhance CREB activity will likely be of benefit in treatment
of AD.50
We have previously reported a chimeric molecule with NO
and GABA-mimetic attributes, 1 (GT-1061), that contains an
MZ pharmacophore (Scheme 1).50 1 significantly improved
learning and memory in rats with cognitive deficits in the
cholinergic systems of the basal forebrain.37 A key objective of
the present study was to determine if 1 is a prototype of an
NO-chimera drug class. A positive observation would allow
further optimization and refinement of this drug class for AD
and other CNS indications. We report herein (1) the
development of a small MZ library, (2) selection of MZ
derivatives based upon neuroprotective activity screened in
primary neurons, (3) synthesis of novel NO-chimeras, coined
nomethiazoles, (4) selection based upon chemical stability, (5)
assay for synaptic rescue in brain slices, (6) assay for restoration
Scheme 2a
aReagents and conditions: (a) Grignard reagent, THF, 0 °C to rt; (b) MsCl, NEt3 and then NaN3, CH3CN, rt; (c) alkyne, CuSO4·5H2O, sodium
ascorbate, t-BuOH/H2O (1:1, v/v); (d) LiAlH4, THF, reflux; (e) MsCl, NEt3 and then NaN3, CH3CN, reflux; (f) MOM-Br, K2CO3, THF; (g)
ethynyltrimethylsilane, CuI, Pd(Ph3P)2Cl2, NEt3, THF; (h) 3, CuSO4·5H2O, sodium ascorbate, K2CO3, MeOH−H2O (2:1); (i) HCl/i-PrOH (1.5
M), 70 °C; (j) 4-nitrooxybutan-1-ol (for 18) or 1-acetoxy-4-hydroxybutane (for 17), Ph3P, DIAD, 0 °C to rt, then K2CO3, MeOH (for 17).
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of learning and memory in vivo, and (7) demonstration of brain
bioavailability and measurement of brain/plasma ratios. The
drug design approach is depicted in Scheme 1.
■ RESULTS AND DISCUSSION
1. Synthesis of MZ Derivatives. Copper(I)-catalyzed
Huisgen [3 + 2]-cycloaddition between an azide and a terminal
alkyne was used to afford regioselectively 1,4-disubstituted-1H-
1,2,3-triazoles, based upon the mild conditions, reliable high
yield, and chemoselectivity of this “click” reaction.51−53 Azide 3
was synthesized in two steps and reacted with commercially
available alkynes, including alkyl (e.g., 1-hexyne, ethynyltrime-
thylsilane, propargylbenzene) and aryl (e.g., ethynylbenzene,
regioisomers of ethynylpyridine, 3-ethynylthiophene, and 5-
ethynyl-1-methyl-1H-imidazole), to generate a small library of
4-methyl-5-(phenyl(1H-1,2,3-triazol-1-yl)methyl)thiazole de-
rivatives (5a−i), and in addition, one fluorinated analogue 8
was also prepared (Scheme 2). The goal was to increase
diversity of MZ derivatives and identify novel neuroprotective
scaffolds. Accordingly 5-(2-(1H-1,2,3-triazol-1-yl)ethyl)-4-
methylthiazole derivatives (11a−c) and two 5-benzyl-4-
methylthiazole derivatives were synthesized (6a,b). Of all the
click products, compound 5d was identified as an excellent
neuroprotectant using in vitro bioassays (discussed below),
whereas removal of the 3-pyridyl substitutent (5i), replacement
of the pyridine ring with phenyl (5b) or other heterocycles (5g,
5h), and changing the position of the nitrogen (5e, 5f) led to
reduced efficacy. A similar structure−activity pattern was
observed for 11a−c. Thus, the 3-(1H-1,2,3-triazole-4-yl)-
pyridine fragment is a potential neuroprotective pharmaco-
phore and was used to develop further MZ derivatives.
Synthesis of MZ analogues, retaining the 5-ethyl-4-
methylthiazole motif of both CMZ and 1, proceeded from 4-
methyl-5-vinylthiazole (19) to yield the alcohols 22 and 23
(Scheme 3). Epoxide intermediate 21 was added dropwise to
Grignard reagents to give 22a−c as major products. Although
the ultimate objective was to modify MZ derivatives as NO-
chimeras, compounds such as the indole derivative 24 served to
extend and explore the MZ structural space. Compound 24 also
represents an analogue of latrepirdine, a once-promising new
AD drug.54 Tetrahydrocarboline, the starting material for 24,
was made according to a published procedure.55 To incorporate
the newly discovered 3-(1H-1,2,3-triazole-4-yl)pyridine phar-
macophore into NO-chimera scaffolds, azido alcohol 25 was
obtained by treating epoxide 21 with sodium azide and reacting
with 3-ethylnylpyridine under standard click chemistry
conditions to give cycloaddition product 26. Compound 31,
a close structural analogue of 26, was synthesized from 22c
using Suzuki coupling to investigate the tolerance of neuro-
protection to triazole ring replacement in the novel
pharmacophore.
2. CMZ Pharmacology Underlying the Design and
Biossay of MZ Derivatives. Many papers have discussed the
biological activity of CMZ in clinical settings and in animal
models. Thiazole derivatives have long been known to manifest
sedative/hypnotic and anticonvulsant effects that are indicative
of GABA-mimetic activity.15,16 The prototype NO-chimera 1
releases 5-(2-hydroxyethyl)-4-methylthiazole (HMZ) as pri-
mary metabolite, which was first reported in 1956 to be an
anticonvulsant agent in rabbits.56 CMZ has been shown
extensively to be neuroprotective in animal models of transient
and global ischemia. CMZ potentiates GABA and muscimol
agonism at the GABAA receptor without evidence for
Scheme 3a
aReagents and conditions: (a) NBS, CH3CO2H, dioxane−H2O; (b) K2CO3, MeOH; (c) Grignard reagent, THF, 0 °C to rt; (d) NaN3, CH3CN/
H2O (1:1, v/v), reflux; (e) NaH, DMSO, 90 °C, 5 h; (f) 3-ethynylpyridine, CuSO4·5H2O, sodium ascorbate, t-BuOH/H2O (1:1, v/v); (g) fuming
HNO3, Ac2O, CH2Cl2, 0 °C; (h) 3-ethynylpyridine, toluene, reflux, 48 h; (i) 2-mercaptoethanol, Na2CO3, CH3CN/H2O (2:1); (j) 3-
pyridineboronic acid, (2-biphenyl)di-tert-butylphosphine, Pd(OAc)2, KF, DMF, 120 °C.
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modulation of levels of GABA itself and opens neuronal Ca-
dependent chloride channels enhancing inhibitory neuro-
transmission. At concentrations 100-fold those required to
potentiate GABA function (30 μM), CMZ is a direct GABAA
receptor agonist.57−59 CMZ is not a ligand for the GABAB or
benzodiazepine receptors and potentiates the actions of glycine
on inhibitory neurotransmission.6−8
The mechanism of action of CMZ appears not to be limited
to GABAA potentiation,
60,61 since CMZ has been claimed to be
a p38-MAPK (mitogen activated protein kinase) pathway
inhibitor, although the exact protein target was not defined.68,69
In Alzheimer’s therapy, inhibition of p38-MAPK is seen as a
target, since, for example, Aβ-mediated inhibition of LTP
involves stimulation of the p38 MAPK cascade.62,63 Compound
4 (Scheme 2) is the lone analogue of CMZ for which
mechanistic data have been reported. In the gerbil model of
global ischemia, protection by R-4 and S-4 was equivalent to
CMZ;6 however, R-4 was reported to be devoid of
anticonvulsant activity, suggested to be compatible with a
mechanism involving GABA reuptake inhibition.7
CMZ has a short half-life and is extensively metabolized.
Oxidative metabolism at carbon α to the thiazole ring leads to
α-hydroxylation and formation of metabolites from further
oxidation, including an α-chloro ketone and aldehyde.64,65 The
replacement of the secondary α-carbon by addition of a group
X (Scheme 1) was justified to prevent metabolic oxidation to
potentially electrophilic metabolites. The primary α-hydroxyl
metabolite of CMZ was also shown to have sedative activity,
providing further reason to limit metabolism at this position.
The rationale for exploration of the structural space represented
by Z (Scheme 1) using aromatic and heterocyclic groups was
based upon the reported biological data on MZ derivative 4
that clearly show central biological actions including neuro-
protection. In the absence of an identified CMZ binding site
associated with a GABAA subunit, iterative extension of the
structural space was carried out by varying the structure and
isomerism, represented by n, X, and Z in Scheme 1.
The selection of a bioassay for iterative design and synthesis
of MZ derivatives was not immediately apparent. Despite the
wealth of reports on CMZ activity in vivo, relatively few
publications have described in vitro assays that could be
adapted for screening of novel MZ analogues and derivatives
for use as neuroprotectants. In SK-N-MC neuroblastoma cells,
CMZ was reported to inhibit the glutamate-induced activation
of AP-1 mediated by NMDA receptor activation.66,67
Immortalized cell cultures (e.g., SK-N-MC and the SH-SY5Y
human neuroblastoma cell lines) would provide a facile system
for cell-based drug screening; however, in SH-SY5Y cell
cultures subject to excitotoxic insults including glutamate,
NMDA, and oxygen−glucose deprivation (OGD), CMZ did
not produce robust and reproducible neuroprotection (data not
shown). Therefore, rat primary cortical neurons were studied as
a more complete neuronal model. Excitotoxic cell death from
treatment with NMDA (100 μM) was inhibited reproducibly
by CMZ treatment and by a number of MZ derivatives and
analogues (Supporting Information, Table S1).
NMDA excitotoxicity represents only one aspect of neuro-
toxicity, whereas OGD provides a much more complete model
simulating ischemia followed by reperfusion inducing ATP
depletion, glutamate release, NMDA receptor overstimulation,
mitochondrial dysfunction, ROS generation, apoptosis, and
proinflammatory cytokine release. Given the evidence that
multiple pathways underlie the anti-inflammatory and neuro-
protective activity of CMZ, OGD in primary neurons was seen
as the preferred model to screen and to correlate structure of
MZ analogues with activity.
The simple 5-ethyl-4-methylthiazole derivatives (22, 23)
studied in primary neuron OGD retained neuroprotective
efficacy comparable to that of CMZ (Table 1). In contrast,
substitution of the phenyl ring in (4-methylthiazol-5-yl)-
(phenyl)methanol derivatives (2 versus 6a and 6b in Table
1) significantly reduced efficacy. Further, O-alkylation of 2 led
to improved neuroprotection (2 versus 38 and 41 in Scheme
4). Compound 26 (Scheme 3) incorporated a 3-(1H-1,2,3-
triazole-4-yl)pyridine pharmacophore within the MZ scaffold.
Both 26 and its regioisomer 30 were protective against OGD,
whereas replacement of the triazole substitutent in 26 (26 vs
31) or substitution of 3-pyridyl in 5d with 2-pyridyl (5e) led to
significant loss of efficacy. The results indicate that both triazole
and 3-pyridyl moieties are critical structural elements to the
neuroprotective 3-(1H-1,2,3-triazole-4-yl)pyridine fragment.
Mindful of the reports of GABAergic and GABA-
independent mechanisms of action for CMZ, the mechanism
of neuroprotection of four MZ derivatives was probed using the
GABAA receptor channel blocker picrotoxin (100 μM) that has
been used extensively for selective antagonism of GABAA
mediated signaling.68−71 Lower concentrations of picrotoxin
deliver only partial blockade,72,73 and some studies employ
higher concentrations.74,75 Muscimol, a potent, selective
Table 1. Relative Percentage Neuroprotection of Primary
Neuronal Cultures in Response to OGD after Treatment
with MZ Derivativesa
% normalized to CMZ after
OGDb




HMZ 14.11 ± 8.5 5a 26.8 ± 5.2
CMZ 100c 5b 57.6 ± 6.7
10 ns 5c 88.3 ± 6.9
22a 99.6 ± 1.4 5d 108 ± 3.6
22b 98.9 ± 3.0 5e 50.9 ± 6.7
23a 102 ± 1.5 5f 90.2 ± 2.2
23b 101 ± 3.9 5g 62.0 ± 3.6
24 15.4 ± 5.9 5h 93.9 ± 1.2
25 ns 5i 58.1 ± 4.2
31 25.0 ± 7.3 8 87.2 ± 3.5





2 94.0 ± 2.9 11a 51.5 ± 11.8
6a 36.8 ± 6.4 11b 53.9 ± 6.8
6b 25.0 ± 4.6 11c 99.6 ± 2.5
38 110.2 ± 12.2
41 114.1 ± 4.6
2-(4-methylthiazol-5-yl)-1H-1,2,3-
triazol-1-ylethanols
26 107.3 ± 2.7
30 92.9 ± 7.3
a% = (drug − DMSO)/(CMZ − DMSO). ns = not studied. Values are
presented as the mean ± SEM (n = 6). bReadings from MTT assay at
24 h normalized to vehicle (0% survival) and CMZ (100% survival).
cComparison, before normalization, with vehicle treated cells
demonstrated a mean increase in cell survival of approximately 30%
caused by CMZ treatment.
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GABAA receptor agonist, was studied for comparison. Instead
of OGD, the simpler excitotoxic insult delivered by glutamate
(100 μM) was used to induce neuronal loss, measured at 24 h
(Figure 1). As anticipated, muscimol produced effective
neuroprotection against glutamate toxicity, which was lost
and reversed on blockade of the GABAA chloride channel.
Neuroprotection produced by 22a mirrored that by muscimol,
indicating a GABAergic neuroprotective mechanism. In
contrast, neuroprotection by 11c was significantly attenuated
by GABAA receptor blockade but was not ablated or reversed,
indicating a neuroprotective mechanism only partially depend-
ent on the GABAA receptor. MZ derivatives 26 and 41
demonstrated intermediate neuroprotective mechanisms. On
the basis of these collected data, a neuroprotective
pharmacophore was speculated (Figure 1). Full elucidation of
the individual GABA-dependent and GABA-independent
pharmacophores requires extended structure−activity studies;
however, the objective was achieved: to develop novel MZ
derivatives to be functionalized as NO-chimeras.
3. Synthesis of NO-Chimeras. MZ derivatives (e.g.,
compounds 5d, 22, 23, and 26, Table 1) were selected for
further study based upon efficacy for neuroprotection against
OGD-induced cell death and the feasibility of structural
modification to give nitrate NO-chimeras. Compound 5d is
as an excellent neuroprotectant against OGD and NMDA
induced cytotoxicity. Compound 16 (Scheme 2) is an analogue
of 5d providing a hydroxyl group on the pyridine ring and
allowing modification as an NO-chimera. A TMS protected
alkyne was introduced into the pyridine derivative 13 via a
Sonogoshira reaction, yielding 14, which underwent direct
reaction with azide 3 in a basic methanolic solution, as adapted
from the literature.76 The MOM protecting group of 15 was
removed, and NO-chimera 18 was prepared by coupling of 16
with 4-nitrooxybutan-1-ol under Mitsunobu conditions. Sim-
ilarly, 17, the denitration product of 18, was made by using 4-
acetyloxybutan-1-ol as reactant followed by deacetylation. Both
16 and 17 are potential metabolites of the NO-chimera 18;
notably 16 retained neuroprotective efficacy comparable to that
of CMZ (Table 1).
Two general strategies were used for synthesis of nitrate NO-
chimeras. The first used simple electrophilic or nucleophilic
nitration procedures to generate nitrate esters from alcohol or
halide intermediates, respectively. For instance, NO-chimeras
32a,b and 33 were prepared from hydroxyl MZ precursors
22a,b and 23a by the treatment of a mixture of acetic anhydride
and fuming nitric acid (Scheme 3). However, this method failed
to directly convert 26 to NO-chimera 28; therefore, nitrate 27
was prepared from intermediate 25 and then reacted with 3-
ethynylpyridine in the presence of ascorbate and CuSO4. The
expected instability of the nitrate moiety under these reductive
conditions led to a low yield of 26 as major and 28 as minor
product. However, a mixture of 25 and alkyne refluxed in
toluene successfully gave both regioisomers 28 and 29 by
thermal cycloaddition. The nitrate group of 29 was removed
using thiol under basic conditions to yield MZ derivative 30
(Scheme 3).
The second strategy of synthesizing NO-chimeras was to
incorporate a labile linker group that would distance the nitrate
from the MZ core in an approach more akin to that used in
hybrid nitrates such as NO-NSAIDs. Esters of cyclopropane
carboxylic acid have been reported to possess substantially
increased stability toward both acid- and base-catalyzed
hydrolysis.77 Inspired by this observation, 1-nitrooxymethylcy-
clopropanecarboxylic acid (35, Scheme 4) was prepared by
mononitration and sequential oxidation. Acid 35 was coupled
with 2 to yield NO-chimera 36 which was expected to have
enhanced stability to esterase hydrolysis and therefore
theoretically predicted to have enhanced brain bioavailability.
An alternative use of this strategy led to design and synthesis of
the carbamate prodrug 42, using the isocyanate precursor
obtained from 4 reacting with mononitrate 34, again predicted
to have further enhanced stability. A similar procedure was used
for coupling of 4-nitrooxybutan-1-ol to yield the carbamate 43.
Preparation of the amide-linked prodrug 44 and compound 37
Scheme 4a
aReagents and conditions: (a) fuming HNO3, Ac2O, CH2Cl2, 0 °C; (b) TEMPO, PhI(OAc)2, DCM; (c) NaClO2, NaH2PO4, 2-methyl-2-butene, t-
BuOH; (d) 35 (for 36, 44) or 1-methylcyclopropane-1-carboxylic acid (for 37), EDCI, DIPEA, HOBT, DCM; (e) NaH, CH3I, DMF; (f) bis(2-
bromomethyl) ether, NaH, DMF; (g) AgNO3, CH3CN, reflux; (h) LiAlH4, THF, reflux; (i) triphosgene, AcOEt, reflux; (j) 34 (for 42) or 4-
nitrooxybutan-1-ol (for 43), NEt3, THF.
Journal of Medicinal Chemistry Article
dx.doi.org/10.1021/jm300353r | J. Med. Chem. 2012, 55, 6784−68016788
Figure 1. Inhibition by picrotoxin of neuroprotection elicited by MZ derivatives in primary neuronal cultures subject to excitotoxic insult. Primary
cortical cultures (10−11 DIV) were subjected to 24 h of glutamate (Glut, 100 μM) toxicity with co-treatment of muscimol (Musc) or MZ derivatives
(50 μM). Picrotoxin (Picro, 100 μM) was added, where indicated, 1 h before glutamate treatment to provide blockade of GABAA signaling. Survival
was measured with the MTT assay and normalized to vehicle treated controls. Data show the mean and SEM from at least six individual experiments
analyzed by ANOVA with post hoc Dunnett’s MCT compared to nonglutamate treated vehicle control or compared to the efficacy of picrotoxin in
blocking each drug treatment effect with a two-tailed t test: ∗, p < 0.05; ∗∗, p < 0.01; ∗∗∗, p < 0.001; ns, not significant.
Figure 2. Representative kinetic traces for hydrolysis of 36 and 37 (10 μM) in phosphate buffer (100 mM, pH 7.4). Incubations were conducted at
room temperature and monitored by HPLC with UV detection at 254 nm and fit to a pseudo-first-order rate equation. A putative mechanism is
shown for rate acceleration by anchimeric stabilization of the anionic transition state by the nitrate group acting as intramolecular Lewis acid.
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allowed comparison with the ester-linked prodrug 36. Aliphatic
nitrate 40 was synthesized from 2 by O-alkylation with
dibromide and subsequent nucleophilic substitution using
AgNO3. The ethylene glycol linker was incorporated to
increase aqueous solubility.
4. Stability of NO-Chimeras. It was anticipated that future
animal studies would require simulation of an extended release
formulation, potentially by use of drug in buffered drinking
water; therefore, the stability of nitrates was tested in phosphate
buffer (100 mM, pH 7.4) using HPLC−UV or LC−MS
monitoring. Since the nitrate group itself is stable in acid and
mild alkaline solution, the observed stability over 5 days at
room temperature of 28, 29, 32a,b, 33, and 40 was expected;
the carbamate 43 and amide 44 were also stable. However, to
our surprise, hydrolysis of 36 was rapid, rather than being
retarded by the hindered α-cyclopropane group, with a half-life
of only about 30 min (Figure 2). The lability of the
nitrooxymethylcyclopropanecarboxylate was unexpected, and
therefore, comparison was made with the stability of 37 as an
analogue lacking only the nitrate group. The observed half-life
of about 380 min for ester hydrolysis confirms that the nitrate
group contributes to the instability of 36. We have previously
reported the phenomenon of accelerated hydrolysis caused by
an adjacent nitrate group ascribed to intramolecular Lewis acid
catalysis78 and propose a similar mechanism for 36 enhanced
by a Thorpe−Ingold effect in which the developing negative
charge is stabilized by the nitrate moiety through a cyclic
transition state (Figure 2). Although more stable than 36,
carbamate 42 also decomposed in phosphate buffer with a half-
life of approximately 3000 min to yield at least four UV-
detectable products that from LC−MS analysis included two
denitrated products (m/z = 333) (Supporting Information,
Figure S1).
5. Restoration of Synaptic Function by NO-Chimeras.
An early event in AD is synaptic failure leading to deficits in
learning and memory.35 The importance of synaptic alterations
in AD has also been confirmed by studies in transgenic mouse
models of AD79 as well as on LTP, a widely studied cellular
model of learning and memory.80 Previous work has reported
that synaptic transmission and cognition are altered in double
transgenic APP/PS1 mice expressing both the human APP
mutation (K670M:N671L) and the human PS1 mutation
(M146L).81,82 In hippocampal slices obtained from APP/PS1
and WT littermates between 4 and 5 months of age,
reproducible LTP responses in the CA1 are observed, with a
reduction of LTP in APP/PS1 hippocampal slices, as measured
by field excitatory postsynaptic potential (fEPSP). Aβ-induced
inhibition of LTP has been observed to be reversed by NO-
donors via a mechanism shown to be mediated by the NO/
cGMP signaling pathway.47 Basal synaptic transmission was
determined by measuring the slope of fEPSP at increasing
stimulus intensities in slices from 4 to 5 month old APP/PS1
mice for NO-chimeras 32a and 42 (100 μM) perfused for 5
min before inducing LTP through a θ-burst tetanic stimulation
of the Schaeffer collateral pathway (Figure 3).81 Potentiation
was observed for 32a, although data for 42 did not reach
significance (P < 0.1). The requirement for reductive
bioactivation of nitrates to NO and the instability of 42
discussed above are likely causes of the observed differences.
The potentiation of the actions of the inhibitory neuro-
transmitter GABA is not expected to enhance LTP, and
accordingly, CMZ did not restore LTP (data not shown).
6. Restoration of Cognition by NO-Chimeras. The step-
through passive avoidance (STPA) task was used to measure
the reversal of a stimulus-response memory deficit induced by
the amnesic agent scopolamine that blocks muscarinic
acetylcholine receptor activation. Since muscarinic acetylcho-
line receptor dysfunction is relevant to AD, scopolamine-
induced amnesia remains a useful model for screening of drugs
for procognitive actions.83 The STPA task tests learned
aversion memory, since mice have a natural preference for
dark areas over brightly lit and open areas. Following a period
of habituation, the animal is placed in the light compartment of
the apparatus and inevitably crosses to the dark compartment
of the apparatus, at which time an electric shock is delivered.
The animals rapidly learn to avoid moving into the dark
compartment during the training phase, despite the admin-
istration of the amnesic agent. Retention of this newly learned
behavior can be tested on subsequent days to assess the
strength of the aversive memory by measuring the latency to
enter the dark area. In both training and testing phases, the task
is halted after 300 s if the animal does not enter the dark side.
STPA has a significant advantage for drug screening because
the potential locomotor effects of drugs are very unlikely to
confound the observations. First, all animals must show a
uniform learning response to training regardless of drug
treatment, which initially entails movement between the
compartments until the task is learned. Second, animals are
Figure 3. Restoration of CA1-LTP impairment in 3-month-old APP/
PS1 mouse hippocampal slices. (A) NO-chimera 32a rescued the LTP
impairment in APP/PS1 mice (F(1,16) = 4.129, p = 0.05, compared with
vehicle; 50−80 min analysis); (B) NO-chimera 42 showed a tendency
toward reversal of LTP impairment without reaching significance
(F(1,12) = 2.537, p = 0.13, compared with vehicle).
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tested 24 and/or 48 h after a single drug treatment, and since
most of the drugs, including all NO-chimeras that we have
studied to date, have cleared the system long before memory is
tested, the STPA task is primarily a measure of memory
consolidation.
Scopolamine was administered 30 min and drugs 20 min
before training (both ip). Drugs were administered at
concentrations equimolar to 1 (1 mg/kg, i.e., 4.45 μmol/kg)
to provide comparison to previous work.84 Administration of
scopolamine and vehicle resulted in a latency of less than 100 s
for mice to enter the dark side of the apparatus when tested 24
h later, demonstrating an inability to consolidate memory. In
contrast, treatment with scopolamine and all novel NO-
chimeras studied (28, 29, 32a, 32b, 40, 42, 43) significantly
restored memory at 24 h (Figure 4).
7. Brain Bioavailability Assessed by LC−MS/MS.
Although the procognitive effects of the NO-chimeras are
indicative of brain bioavailability, LC−MS/MS measurements
were used to confirm blood−brain barrier penetration.
Furthermore, a second objective of these assays was to measure
the concentrations of MZ metabolites in the brain after NO-
chimera delivery, since the neuroprotective properties of the
MZ metabolite are an important aspect of the drug design.
Figure 5 shows LC−MS/MS chromatograms for multiple
reaction monitoring (MRM) after administration of two NO-
chimeras and their MZ metabolites, representing two subclasses
of NO-chimera with different physicochemical properties. The
NO-chimera 32a showed good brain bioavailability, and its 5-
ethyl-4-methylthiazole metabolite 22a was also observed in the
brain of mice 20 min after administration. In contrast, the
bioavailability of NO-chimera 28 was low at this time point,
whereas the 2-(4-methylthiazol-5-yl)-1H-1,2,3-triazol-1-yletha-
nol metabolite 26 was readily detected. Calculated parameters
suggest that 26 (tPSA = 73 Å2; ClogP < 0) should not
penetrate the blood−brain barrier, whereas 22a (tPSA = 33 Å2;
ClogP = 1.56) has more favorable properties; however, both
MZ derivatives were observed in mouse brains after direct ip
administration or after administration of the NO-chimera
prodrug. The preliminary replicate analyses after administration
of 26 and 28 suggest that the nitrate chimera prodrug elevates
brain levels of 26, relative to direct administration of 26 itself
(Table 2). These data, obtained after ip administration, are
predictive of oral bioavailability by comparison with data for
1.37
■ CONCLUSIONS
Synaptic failure is an early event in both AD and mild cognitive
impairment (MCI), which causes impaired cognition and
memory.1 Disease progression involves neurodegeneration of
cortical and hippocampal neurons and loss of hippocampal
volume. A drug that targets synaptic failure in addition to
providing neuroprotection is a rational approach to AD
therapy. Abnormally assembled Aβ and tau proteins are
associated with both synaptic and neuronal dysfunction and
loss.3 Aβ has been shown to down-regulate signaling via the
NO/cGMP/CREB pathway; therefore, enhancement of NO/
cGMP signaling and activation of CREB may provide a novel
approach for the treatment of AD.39−42,47,85 Gene products
associated with CREB activation may provide neuroprotection;
however, prevention of neuronal loss can also be achieved by
selective pharmacological modulation of GABAA receptors, a
mechanism that has been shown to provide neuroprotection
against Aβ mediated toxicity.86−89
Herein, we have elaborated on the concept of an NO-
chimera, incorporating GABA-mimetic and NO-mimetic
mechanisms, by developing and derivatizing novel MZ
scaffolds. These chimeric agents represent a novel drug class
coined nomethiazoles. The milestones for this study were (1)
development of the MZ pharmacophore through synthesis of
novel derivatives, (2) assay of neuroprotection in primary
neurons, (3) synthesis of nomethiazoles by derivatization of
novel, neuroprotective MZ scaffolds, possessing (4) satisfactory
stability. Proof-of-concept for nomethiazoles was achieved by
demonstration of (5) synaptic rescue using LTP measurements
ex vivo, (6) restoration of learning and memory in vivo, and (7)
brain bioavailability of both NO-chimeras and their MZ
metabolites. It was confirmed that 1 is a prototype of a novel
drug class that possesses a combination of GABA-mimetic and
NO-mimetic activities, thus providing both neuroprotection
and neurorestoration. Since neurodegenerative diseases such as
AD are multifactorial, the development of drugs designed to
target more than one mechanism of action is likely to be a
promising therapeutic approach.
■ EXPERIMENTAL SECTION
Synthesis. 1H and 13C NMR spectra were obtained with Bruker
Ultrashield 400 MHz and Advance 300 MHz spectrometers. Chemical
shifts are reported as δ values in parts per million (ppm) relative to
tetramethylsilane (TMS) for all recorded NMR spectra. All reagents
and solvents were obtained commercially from Acros, Aldrich, and
Fluka and were used without purification. Low-resolution mass
spectrometry (LRMS) was conducted on an Agilent 6300 ion-trap
LC−MS instrument. High resolution mass spectral data were collected
using a Shimadzu QTOF 6500 instrument. All compounds submitted
for biological testing were found to be >95% pure by analytical HPLC.
Purity and/or low resolution mass spectral (ESI or APCI) analysis was
measured using an Agilent Zorbax Bonus C18, 3.5 μm, 150 mm × 3.0
mm column on either a Shimadzu UFLC or Agilent 1100 series HPLC
instrument in tandem with an Agilent 6310 ion trap LC−MS
instrument. HPLC parameters were the following: 0.1% FA in 10%
CH3OH (solvent A); 0.1% FA in CH3CN (solvent B); flow rate 0.5
mL/min; gradient, t = 0 min, 10% A; t = 1 min, 10% A; t = 18 min,
80% A; t = 20 min, 80% A; t = 21 min, 95% A.
1-(4-Methyl-5-thiazolyl)-1-phenylmethanol (2). 4-Methyl-5-
thiazolecarboxaldehyde (1.0 g, 7.8 mmol) was dissolved in THF (40
mL) and cooled in an ice bath, and phenylmagnesium bromide (1 M
in THF, 8.5 mL) was added dropwise. The reaction mixture was
Figure 4. Procognitive effects of NO-chimeras evaluated in the
scopolamine-induced memory deficit model using the STPA task.
Scopolamine was administered 30 min and drug was administered 20
min prior to the start of training, and memory was tested 24 h after
training and drug treatment. NO-chimeras 28, 29, 32a, 32b, 42, 43
(∗∗∗, p < 0.01, compared with vehicle), and 40 (∗∗, p < 0.05,
compared with vehicle) significantly reversed the scopolamine induced
memory deficit. Data were obtained from at least five mice per group.
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warmed to room temperature and stirred overnight. The reaction was
quenched with aqueous NH4Cl, and extraction was with ethyl acetate
(2 × 100 mL). Organic solutions were combined and concentrated,
and the crude product was purified by column chromatography
(hexanes/ethyl acetate, 1:1, 1.4 g, 87%). 1H NMR (acetone-d6, 400
MHz): δ 8.81 (s, 1H), 7.45(d, 2H, J = 7.2 Hz) 7.24−7.36 (m, 3H),
6.16 (d, 1H, J = 3.6 Hz), 5.34 (d, 1H, J = 3.6 Hz), 2.38 (s, 3H). 13C
NMR (acetone-d6, 100 MHz): δ 151.57, 148.90, 145.14, 137.96,
129.09, 128.20, 126.92, 69.66, 15.54.
5-(Azidophenylmethyl)-4-methylthiazole (3). MsCl (2.9 mL)
was added to a solution of 2 (6.2 g) and NEt3 (6.0 mL) in anhydrous
acetonitrile (70 mL). Reaction was monitored by TLC until the
starting material was consumed. NaN3 (6.1 g) was added, and the
mixture was stirred at room temperature overnight. Most of the
acetonitrile was removed under reduced pressure. The residue was
diluted with ethyl acetate and washed with water. The organic phase
was separated and concentrated, and the crude product was purified by
column chromatography (hexane/ethyl acetate, 2:1, 75%). 1H NMR
(acetone-d6, 400 MHz): δ 8.87 (s, 1H), 7.34−7.47 (m, 5H), 6.41 (s,
1H), 2.45 (s, 3H). 13C NMR (acetone-d6, 100 MHz): δ 152.86,
151.16, 140.13, 131.97, 129.67, 129.24, 127.62, 61.78, 15.55. HRMS
calcd for C11H10N4S [M + H]
+ 231.0704, found 231.0713.
α-Phenyl-(4-methyl-5-thiazolyl)methanamine (4). LiAlH4
(130 mg, 3.5 mmol) was added to a solution of 3 (320 mg, 1.39
mmol) in anhydrous THF (10 mL). The mixture was refluxed for 1 h
and quenched with 0.1 N NaOH. The residue was diluted with water
and extracted using ethyl acetate (2 × 25 mL). Organic solutions were
combined and concentrated, and the crude product was purified by
column chromatography (DCM/MeOH, 15:1, 230 mg, 82%). 13C
Figure 5. MRM LC−MS/MS chromatograms of extracted mouse brain samples 20 min after ip delivery of each drug at a dosage that was equimolar
with 1 (4.5 μmol/kg): (A) 26 with 8 used as internal standard; (B) 28 with 8 used as internal standard; (C) 22a with 22b used as internal standard;
(D) 32a with 22b used as internal standard.
Table 2. Analysis of Selected MZ Derivatives and NO-










28 28 333 → 288 8, 352 → 147 2.1 ± 0.6
28 26 288 → 147 8, 352 → 147 76.6 ± 10.2
26 26 288 → 147 8, 352 → 147 56.4 ± 5.5
32a 32a 265 → 220 22b, 238 → 207 9.5 ± 0.6
32a 22a 220 → 189 22b, 238 → 207 9.5 ± 1.1
22a 22a 220 → 189 22b, 238 → 207 32.9 ± 3.7
aFour mice were used for the injection of each drug. Values are
presented as the mean ± SEM (n = 4).
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NMR (CD3CN, 100 MHz): δ 151.62, 148.35, 145.96, 139.76, 129.52,
128.23, 127.51, 53.69, 15.61. HRMS calcd for C11H12N2S [M + H]
+
205.0799, found 205.0807.
Compound 5. Standard Click Chemistry Procedure. Azide (1
equiv) and alkyne (1 equiv) were dissolved in t-BuOH and water
(1:1). Sodium ascorbate (0.2 equiv) and CuSO4·5H2O (0.1 equiv)
were added. The reaction mixture was stirred overnight, diluted with
ethyl acetate, and washed with water. The organic phase was separated
and concentrated, and the crude product was purified by column
chromatography (DCM/MeOH, 20:1, yield 75−90%). For com-
pounds 5i and 11a, the solvent was changed to a mixture of MeOH
and H2O (2:1, v/v). K2CO3 (1 equiv) was also added in addition to
other reactants.
4-Butyl-1-[(4-methyl-5-thiazolyl)phenylmethyl]-1H-1,2,3-tri-
azole (5a). 1-Hexyne was reacted with 3 to give 5a. 1H NMR
(acetone-d6, 400 MHz): δ 8.92 (s,1H), 7.83 (s, 1H), 7.48 (s, 1H),
7.35−7.41(m, 3H), 7.27−7.28 (m, 2H), 2.68 (t, 2H, J = 8.0 Hz), 2.36
(s, 3H), 1.58−1.66 (m, 2H), 1.29−1.38 (m, 2H), 0.88 (t, 3H, J = 7.6
Hz). 13C NMR (acetone-d6, 100 MHz): δ 153.50, 152.51, 148.66,
140.45, 131.10, 129.67, 129.34, 127.72, 122.08, 61.08, 32.23, 25.86,




triazole (5b). Ethynylbenzene was reacted with 3 to give 5b. 1H
NMR (acetone-d6, 400 MHz): δ 9.02 (s, 1H), 8.48 (s, 1H), 7.92−7.94
(m, 2H), 7.58 (s, 1H), 7.30−7.45 (m, 8H), 2.41 (s, 3H). 13C NMR
(acetone-d6, 100 MHz): δ 147.98, 140.23, 131.82, 129.77, 129.55,
129.48, 128.75, 127.74, 126.29, 121.31, 61.47, 15.47. HRMS calcd for
C19H16N4S [M + H]
+ 333.1174, found 333.1186.
1-[(4-Methyl-5-thiazolyl)phenylmethyl]-4-(phenylmethyl)-
1H-1,2,3-triazole (5c). Propargylbenzene was reacted with 3 to give
5c. 1H NMR (DMSO-d6, 400 MHz): δ 8.98 (s, 1H), 7.97 (s, 1H), 7.53
(s, 1H), 7.17−7.41 (m, 10H), 4.01 (s, 2H), 2.31 (s, 3H). 13C NMR
(CDCl3, 100 MHz): δ 153.82, 150.92, 146.33, 139.46, 139.36, 129.81,
128.99, 128.57, 128.52, 126.81, 126.29, 122.78, 59.37, 31.19, 15.05.
HRMS calcd for C20H18N4S [M + H]
+ 347.1330, found 347.1344.
3-[1-[(4-Methyl-5-thiazolyl)phenylmethyl]-1H-1,2,3-triazol-
4-yl]pyridine (5d). 3-Ethynylpyridine was reacted with 3 to give 5d.
1H NMR (DMSO-d6, 400 MHz): δ 9.10 (bs, 1H), 9.03 (s, 1H), 8.83
(s, 1H), 8.54 (bs,1H), 8.25 (d, 1H, J = 8.0 Hz), 7.67 (s, 1H), 7.29−
7.49 (m, 6H), 2.45 (s, 3H). 13C NMR (DMSO-d6, 100 MHz): δ
153.98, 151.42, 149.12, 146.58, 143.77, 139.09, 132.71, 129.48, 129.08,
128.76, 126.87, 126.41, 124.08, 122.18, 59.87, 15.12. HRMS calcd for
C18H15N5S [M + H]
+ 334.1126, found 334.1118.
2-[1-[(4-Methyl-5-thiazolyl)phenylmethyl]-1H-1,2,3-triazol-
4-yl]pyridine (5e). 2-Ethynylpyridine was reacted with 3 to give 5e.
1H NMR (acetone-d6, 400 MHz): δ 8.95 (s, 1H), 8.55 (d, 1H, J = 4.0
Hz), 8.51 (s, 1H), 8.15 (d, 1H, J = 8.0 Hz), 7.85 (triple doublet, 1H, J
= 8.0, 1.6 Hz), 7.64 (s, 1H), 7.21−7.45 (m, 6H), 2.43 (s, 3H). 13C
NMR (acetone-d6, 100 MHz): δ 153.73, 152.61, 151.51, 150.42,
148.90, 140.03, 137.59, 130.37, 129.79, 129.51, 127.74, 123.69, 123.32,




4-yl]pyridine (5f). 4-Ethynylpyridine was reacted with 3 to give 5f.
1H NMR (CDCl3, 400 MHz): δ 8.75 (s, 1H), 8.61 (d, 2H, J = 4.8 Hz),
8.01 (s, 1H), 7.71 (d, 2H, J = 5.6 Hz), 7.34−7.40 (m, 4H), 7.18−7.20
(m, 2H), 2.42 (s, 3H). 13C NMR (CDCl3, 100 MHz): δ 152.49,
151.94, 150.09, 145.12, 137.55, 137.39, 129.02, 128.99, 128.81, 126.46,




1,2,3-triazole (5g). 3-Ethynylthiophene was reacted with 3 to give
5g. 1H NMR (CDCl3, 400 MHz): δ 8.74 (s, 1H), 7.69 (d, 1H, J = 2.0
Hz), 7.60 (s, 1H), 7.36−7.44 (m, 5H), 7.30 (s, 1H), 7.15−7.16 (m,
2H), 2.43 (s, 3H). 13C NMR (CDCl3, 100 MHz): δ 152.43, 152.16,
144.17, 138.07, 131.47, 129.34, 129.17, 129.08, 126.70, 126.40, 125.73,





dazole was reacted with 3 to give 5h. 1H NMR (CDCl3, 400 MHz): δ
8.75 (s, 1H), 7.70(s, 1H), 7.50 (bs, 2H), 7.39−7.40 (m, 3H), 7.31(s,
1H), 7.17−7.19 (m, 2H), 3.93 (s, 3H), 2.44 (s, 3H). 13C NMR
(CDCl3, 100 MHz): δ 152.50, 151.87, 137.66, 129.04, 128.99, 128.90,




(5i). Ethynyltrimethylsilane was reacted with 3 in the presence of
CuSO4, sodium ascorbate, and K2CO3 to give 5i.
1H NMR (acetone-
d6, 400 MHz): δ 8.90 (s, 1H), 8.06 (d, 1H, J = 0.8 Hz), 7.75 (s, 1H, J =
0.8 Hz), 7.57 (s, 1H), 7.26−7.43 (m, 5H), 2.37 (s, 3H). 13C NMR
(acetone-d6, 100 MHz): δ 153.57, 152.41, 140.39, 134.11, 130.73,
129.73, 129.42, 127.71, 125.00, 61.00, 15.35. HRMS calcd for
C13H12N4S [M + H]
+ 257.0861, found 257.0873.
1-(4-Methyl-5-thiazolyl)-1-(4-fluorophenyl)methanol (6a). 4-
Fluorophenylmagnesium bromide was reacted with 1 to give 6a
according to the method described for compound 2. 1H NMR
(CDCl3, 400 MHz): δ 8.49 (s, 1H), 7.33−7.37 (m, 2H), 7.03 (t, 2H, J
= 8.4 Hz), 6.04 (s, 1H), 2.32 (s, 3H). HRMS calcd for C11H10FNOS
[M + H]+ 224.0545, found 224.0544.
1-(4-Methyl-5-thiazolyl)-1-(4-chlorophenyl)methanol (6b). 4-
Chlorophenylmagnesium bromide was reacted with 1 to give 6b
according to the method described for compound 2. 1H NMR
(CDCl3, 400 MHz): δ 8.56 (s, 3H), 7.33 (bs, 4H), 6.07 (s, 1H), 2.38




was used to prepare 7 according to the method described for
compound 3. 1H NMR (CDCl3, 400 MHz): δ 8.69 (s, 1H), 7.27−7.34
(m, 2H), 7.07 (t, 2H, J = 8.4 Hz), 5.98 (s, 1H), 2.43 (s, 3H). 13C NMR
(CDCl3, 100 MHz): δ 163.82, 161.35, 151.85, 150.28, 134.43, 134.40,
130.92, 128.60, 128.52, 115.98, 115.77, 60.74, 15.49.
3-[1-[(4-Fluorophenyl)(4-methyl-5-thiazolyl)methyl]-1H-
1,2,3-triazol-4-yl]pyridine (8). 3-Ethylnylpyridine was reacted with
7 to give 8 using a method described for compound 5. 1H NMR
(CDCl3, 400 MHz): δ 8.99 (s, 1H), 8.77 (s, 1H), 8.56 (d, 1H, J = 3.6
Hz), 8.18−8.21 (m, 1H), 7.88 (s, 1H), 7.34−7.37 (m, 2H), 7.17−7.20
(m, 2H), 7.06−7.11 (m, 2H), 2.44 (s, 3H). 13C NMR (CDCl3, 100
MHz): δ 163.97, 161.49, 152.59, 152.09, 149.33, 146.89, 144.89,
113.71, 113.68, 132.89, 128.79, 128.61, 128.53,126.16, 123.60, 119.27,
116.26, 116.04, 60.42, 15.30. . HRMS calcd for C18H14FN5S [M + H]
+
352.1032, found 352.1040.
5-(2-Azidoethyl)-4-methylthiazole (10). MsCl (2.1 g, 18.1
mmol) was added to a solution of 9 and DIPEA (3.7 mL, 22.3
mmol) in anhydrous acetonitrile (100 mL). Reaction was monitored
by TLC until the starting material was consumed. NaN3 (2.7 g, 41.9
mmol) was added, and the mixture was refluxed for 3 h. Most of the
acetonitrile was removed under reduced pressure. The residue was
diluted with ethyl acetate and washed with water. The organic phase
was separated and concentrated, and the crude product was purified by
column chromatography. Product was obtained as a slightly yellow oil.
1H NMR (acetone-d6, 400 MHz): δ 8.74 (s, 1H), 3.59 (t, 2H, J = 6.8
Hz), 3.09 (t, 2H, J = 6.8 Hz), 2.38 (s, 3H). 13C NMR (acetone-d6, 100
MHz): δ 150.75, 128.19, 52.72, 26.54, 14.96.
Compound 11. 11a−c were synthesized using the method
described for compound 5.
1-[2-(4-Methyl-5-thiazolyl)ethyl]-1H-1,2,3-triazole (11a).
Ethynyltrimethylsilane was reacted with 10 in the presence of
CuSO4, sodium ascorbate, and K2CO3 to give 11a.
1H NMR
(acetone-d6, 400 MHz): δ 8.70 (s, 1H), 7.83 (s, 1H), 7.62 (s, 1H),
4.68 (t, 2H, J = 6.8 Hz), 3.45 (t, 2H, J = 6.8 Hz), 2.18 (s, 3H). 13C
NMR (acetone-d6, 100 MHz): δ 151.12, 150.93, 133.81, 127.25,




(11b). Ethynylbenzene was reacted with 10 to give 11b. 1H NMR
(CDCl3, 400 MHz): δ 8.60 (s, 1H), 7.76−7.78 (m, 2H), 7.51 (s, 1H),
7.39−7.43 (m, 2H), 7.31−7.35 (m, 1H), 4.60 (t, 2H, J = 6.8 Hz), 3.44
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(t, 2H, J = 6.8 Hz), 2.25 (s, 3H). 13C NMR (CDCl3, 100 MHz): δ
150.73, 150.32, 147.78, 130.32, 128.80, 128.20, 125.84, 125.69, 119.94,




pyridine (11c). 3-Ethynylpyridine was reacted with 10 to give 11c.
1H NMR (CDCl3, 400 MHz): δ 8.95 (s, 1H), 8.61 (s, 1H), 8.56 (d,
1H, J = 3.6 Hz), 8.13−8.15 (m, 1H), 7.70 (s, 1H), 7.34−7.37 (m, 1H),
4.64 (t, 2H, J = 6.8 Hz), 3.47 (t, 2H, J = 6.8 Hz), 2.26 (s, 3H). 13C
NMR (CDCl3, 100 MHz): δ 150.82, 150.40, 149.33, 147.01, 144.73,
132.98, 126.49, 125.66, 123.74, 120.35, 51.23, 27.31, 14.61. HRMS
calcd for C13H13N5S [M + H]
+ 272.0970, found 272.0965.
3-Bromo-5-(methoxymethoxy)pyridine (13). 3-Bromo-5-hy-
droxypyridine (1.0 g, 5.7 mmol) and MOM-Br (0.64 mL, 6.9
mmol) were dissolved in THF(10 mL). Anhydrous K2CO3 (1.5 g, 10.9
mmol) was added, and the reaction mixture was stirred overnight.
After filtration and concentration, the product was purified by column
chromatography (SiO2, hexane/ethyl acetate, 3:1, 1.1 g, 88%).
1H
NMR (CDCl3, 400 MHz): δ 8.34 (s, 1H), 8.33 (s, 1H), 7.56 (t, 1H, J
= 2.4 Hz), 5.19 (s, 2H), 3.49 (s, 3H). 13C NMR (CDCl3, 100 MHz): δ
153.70, 143.96, 137.81, 125.72, 120.18, 94.66, 56.27.
3-(Methoxymethoxy)-5-[2-(trimethylsilyl)ethynyl]pyridine
(14). Compound 13 (1.0 g, 4.6 mmol), CuI (44 mg, 0.23 mmol), and
Pd(Ph3P)2Cl2 (162 mg, 0.23 mmol) were placed in a flask and filled
with argon. THF (10 mL) was added using a syringe followed by NEt3
(3.0 mL, 21 mmol) and ethynyltrimethylsilane (0.7 mL, 5.1 mmol).
The reaction mixture was stirred overnight at room temperature. Most
of the solvent was removed, and the residue was purified by column
chromatography (SiO2, hexane/ethyl acetate, 5:1, 0.85 g, 81%).
1H
NMR (CDCl3, 400 MHz): δ 8.32−8.35 (m, 2H), 7.43−7.44 (m, 2H),
5.19 (s, 2H), 3.48 (s, 3H), 0.26 (s, 9H). 13C NMR (CDCl3, 100
MHz): δ 152.65, 145.97, 139.21, 125.18, 120.38, 101.15, 98.03, 94.53,
56.17.
3-(Methoxymethoxy)-5-[1-[ (4-methyl-5-thiazolyl ) -
phenylmethyl]-1H-1,2,3-triazol-4-yl]pyridine (15). Azide 3 (783
mg, 3.4 mmol) and alkyne 14 (0.8 g, 3.4 mmol) were dissolved in a
mixture of MeOH and water (2:1, 5 mL). K2CO3 (484 mg, 3.5 mmol),
CuSO4·5H2O (170 mg, 0.68 mmol), and sodium ascorbate (272 mg,
0.68 mmol) were added, and the reaction mixture was stirred at room
temperature overnight. Most of the solvent was removed under
reduced pressure. The residue was dissolved in DCM and washed with
water. The organic phase was separated and concentrated, and the
crude product was purified by column chromatography (DCM/
MeOH, 20:1, 1.15 g, 86%). 1H NMR (CDCl3, 400 MHz): δ 8.75 (s,
1H), 8.65 (s, 1H), 8.37 (s, 1H), 7.92 (s, 1H), 7.90 (s, 1H), 7.35−7.39
(m, 4H), 7.18−7.20 (m, 2H), 5.24 (s, 2H), 3.48 (s, 3H), 2.43 (s, 3H).
13C NMR (CDCl3, 100 MHz): δ 153.40, 152.50, 151.92, 144.42,
140.07, 139.05, 137.69, 129.01, 128.96, 128.92, 126.79, 126.51, 119.70,
119.48, 94.31, 60.93, 56.03, 15.20.
5-[1-[(4-Methyl-5-thiazolyl)phenylmethyl]-1H-1,2,3-triazol-
4-yl]-3-pyridinol (16). Click product 15 (230 mg, 0.58 mmol) was
dissolved in HCl/i-PrOH solution (1.5M, 5.0 mL) and heated at 70
°C for 1 h. The solvent was removed. The residue was dissolved in
AcOEt and washed with aqueous NaHCO3. The organic phase was
separated and concentrated, and the crude product was purified by
column chromatography (DCM/MeOH, 15:1, 170 mg, 83%). 1H
NMR (acetone-d6, 400 MHz): δ 9.11 (bs, 1H), 8.93 (s, 1H), 8.61 (s,
1H), 8.59 (s, 1H), 8.17 (d, 1H, J = 2.8 Hz), 7.76 (t, 1H, J = 2.4 Hz),
7.60 (s, 1H), 7.35−7.46 (m, 5H), 2.41 (s, 3H). 13C NMR (acetone-d6,
100 MHz): δ154.63, 153.77, 152.72, 145.09, 140.14, 139.11, 138.41,
130.41, 129.83, 129.56, 128.41, 127.78, 122.09, 119.22, 61.50, 15.43.
HRMS calcd for C18H15N5OS [M + H]
+ 350.1076, found 350.1068.
4-[5-[1-[(4-Methyl-5-thiazolyl)phenylmethyl]-1H-1,2,3-tria-
zol-4-yl]-3-pyridinyl]oxy-1-butanol (17). 1-Acetoxy-4-hydroxybu-
tane (150 mg, 1.2 mmol), 16 (200 mg, 0.57 mmol), and PPh3 (227
mg) were dissolved in THF (5 mL), and the flask was filled with
argon. The solution was cooled in an ice bath, and DIAD (230 μL, 1.1
mmol) was added using a syringe. The mixture was stirred overnight
and quenched with water. After workup, the crude product was
dissolved in methanol (10 mL) and treated with K2CO3 (140 mg).
Solvent was removed, and the residue was dissolved in ethyl acetate
and washed with water. The crude product was purified by column
chromatography (DCM/MeOH, 15:1, 67 mg, 28%). 1H NMR
(CDCl3, 400 MHz): δ 8.76 (s,1H), 8.50 (d, 1H, J = 0.8 Hz), 8.24
(d, 1H, J = 2.4 Hz), 7.84 (s,1H), 7.77 (t, 1H, J = 1.6 Hz), 7.39−7.41
(m, 3H), 7.33 (s,1H), 7.17−7.19 (m, 2H), 4.10 (t, 2H, J = 6.4 Hz),
3.73 (t, 2H, J = 6.4 Hz), 2.44 (s, 3H), 1.89−1.94 (m, 2H), 1.74−1.79
(m, 2H). 13C NMR (CDCl3, 100 MHz): δ 155.30, 152.60, 152.09,
144.66, 138.82, 138.13, 137.74, 129.19, 129.16, 129.06, 126.84, 126.64,
119.58, 117.38, 68.19, 62.01, 61.11, 29.07, 25.55, 15.35. HRMS calcd
for C22H23N5O2S [M + H]
+ 422.1645, found 422.1657.
4-[[5-[1-[(4-Methyl-5-thiazolyl)phenylmethyl]-1H-1,2,3-tria-
zol-4-yl]-3-pyridinyl]oxybutane]-1-nitrate (18). 1-Nitrooxy-4-hy-
droxybutane (25 mg, 0.19 mmol), 16 (25 mg, 0.07 mmol), and PPh3
(37 mg, 0.14 mmol) were dissolved in THF (2 mL), and the flask was
filled with argon. The solution was cooled in an ice bath, and DIAD
(40 μL) was added using a syringe. The mixture was stirred overnight
and quenched with water. Solvent was removed, and crude product
was purified by purified by column chromatography (DCM/MeOH,
20:1, 67%). 1H NMR (CDCl3, 400 MHz): δ 8.77 (s, 1H), 8.53 (s,
1H), 8.26 (s, 1H), 7.81 (s, 1H), 7.80−7.79 (m, 1H), 7.40−7.42 (m,
3H), 7.33 (s, 1H), 7.17−7.19 (m, 2H), 4.55 (t, 2H, J = 6.0 Hz), 4.12
(t, 2H, J = 6.0 Hz), 2.45 (t, 3H), 1.95−1.97 (m, 4H). 13C NMR
(CDCl3, 100 MHz): δ155.14, 152.65, 152.24, 144.67, 139.20, 138.14,
137.81, 129.29, 129.26, 129.09, 126.98, 126.72, 119.54, 117.39, 72.70,
67.47, 61.21, 25.47, 23.71, 15.45. HRMS calcd for C22H22N6O4S [M +
H]+ 467.1501, found 467.1488.
α-(Bromomethyl)-4-methyl-5-thiazolemethanol (20). 4-
Methyl-5-vinylthiazole (900 mg, 7.2 mmol) was dissolved in a mixture
of dioxane (2.5 mL), H2O (5 mL) and acetic acid (430 mg). NBS (1.4
g, 7.9 mmol) was added in three portions. The reaction mixture was
stirred at room temperature for 1 h and then diluted with ethyl acetate
(50 mL). The organic phase was separated and concentrated, and the
product was purified by column chromatography (SiO2, hexane/ethyl
acetate, 1.5:1, 900 mg, 52%). 1H NMR (CDCl3, 400 MHz): δ 8.64 (s,
1H), 5.22 (t, 1H, J = 6.8 Hz), 3.57 (d, 2H, J = 6.8 Hz), 2.42 (s, 3H).
13C NMR (CDCl3, 100 MHz): δ 151.53, 149.48, 132.10, 67.63, 38.44,
15.39.
4-Methyl-5-(2-oxiranyl)thiazole (21). Bromohydrin 20 (650 mg,
2.94 mmol) was dissolved in MeOH (10 mL). K2CO3 (1.2 g, 8.8
mmol) was added, and the reaction mixture was stirred at room
temperature for 1 h. Solvent was removed under reduced pressure, and
the residue was diluted with hexane and ethyl acetate (50 mL, 2:1 v/
v). After filtration and concentration, the product was obtained with
enough purity for the next step reaction. 1H NMR (CDCl3, 400
MHz): δ 8.63 (s, 1H), 4.10 (t, 1H, J = 3.6 Hz), 3.22−3.24 (m, 1H),
2.91−2.93 (m, 1H), 2.53 (s, 3H). 13C NMR (CDCl3, 100 MHz): δ
151.90, 150.69, 128.97, 51.25, 46.80, 14.95.
β-Phenyl-4-methyl-5-thiazoleethanol (22a) and α-(Phenyl-
methyl)-4-methyl-5-thiazolemethanol (23a). Crude epoxide 21
(1.0 g, 7.1 mmol) was dissolved in anhydrous THF (10 mL) and
added dropwise to a phenylmagnisum bromide solution (1 M in THF,
10 mL) at 4 °C. The reaction mixture was stirred overnight at room
temperature, quenched with aqueous NH4Cl, and extracted with ethyl
acetate (2 × 50 mL). The organic phase was separated and
concentrated. 22a and 23a were separated and purified by column
chromatography (SiO2, hexane/ethyl acetate 1:1). 22a (major product,
1.0 g, 65%), 1H NMR (CDCl3, 400 MHz): δ 8.43 (s, 1H), 7.25−7.29
(m, 2H), 7.17−7.21 (m, 3H), 4.38 (t, 1H, J = 6.4 Hz), 3.95−4.05 (m,
2H), 3.87 (s, 1H, OH), 2.28 (s, 3H). 13C NMR (CDCl3, 100 MHz): δ
150.11, 149.87, 140.13, 131.48, 128.92, 127.91, 127.33, 67.13, 46.27,
15.34. HRMS calcd for C12H13NOS [M + H]
+ 220.0796, found
220.0795. 23a (minor product, 0.2 g, 13%), 1H NMR (CDCl3, 400
MHz): δ 8.43 (s, 1H), 7.28−7.33 (m, 5H), 4.83 (t, 1H, J = 6.4 Hz),
3.29 (s, 1H), 3.10−3.19 (m, 2H), 2.17 (s, 3H). 13C NMR (CDCl3, 100
MHz): δ 150.07, 149.89, 143.23, 128.42, 127.82, 126.95, 125.77, 74.36,
36.08, 14.63. HRMS calcd for C12H13NOS [M + H]
+ 220.0796, found
220.0796.
β-(4-Fluorophenyl)-4-methyl-5-thiazoleethanol (22b) and α-
[(4-Fluorophenyl)methyl]-4-methyl-5-thiazolemethanol (23b).
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22b and 23b were synthesized using the procedure described above for
22a from epoxide 21 and 4-fluorophenylmagnisum bromide. Products
were separated and purified by column chromatography (SiO2,
hexane/ethyl acetate, 1:1). 22b (major product, 60%), 1H NMR
(CDCl3, 400 MHz): δ 8.45 (s, 1H), 7.16−7.19 (m, 2H), 6.30−6.97
(m, 2H), 4.37 (t, 1H, J = 6.4 Hz), 3.94−4.03 (m, 2H), 2.26 (s, 3H).
13C NMR (CDCl3, 100 MHz): δ 162.66, 160.22, 150.07, 148.95,
136.24, 136.21, 131.98, 129.26, 129.18, 115.36, 115.14, 66.22, 45.16,
14.82. HRMS calcd for C12H12FNOS [M + H]
+ 238.0702, found
238.0699. 23b (minor product, 14%), 1H NMR (CDCl3, 400 MHz): δ
8.39 (s, 1H), 7.21−7.24 (m, 2H), 6.96−6.99 (m, 2H), 4.81 (t, 1H, J =
6.4 Hz), 3.04−3.16 (m, 2H), 2.12 (s, 3H). 13C NMR (CDCl3, 100
MHz): δ 163.50, 161.06, 150.25, 149.84, 139.14, 139.11, 127.51,
127.43, 126.89, 115.35, 115.14, 73.62, 36.19, 14.61. HRMS calcd for
C12H12FNOS [M + H]
+ 238.0702, found 238.0709.
β-(4-Chlorophenyl)-4-methyl-5-thiazoleethanol (22c). Com-
pound 22c was synthesized using the procedure described above for
22a from epoxide 21 and 4-chlorophenylmagnisum bromide (1 M in
diethyl ether). Product was separated and purified by column
chromatography (SiO2, hexane/ethyl acetate, 1:1, 79%).
1H NMR
(CDCl3, 400 MHz): δ 8.61 (s, 1H), 7.29 (d, 2H, J = 8.4 Hz), 7.18 (d,
2H, J = 8.4 Hz), 4.42 (t, 1H, J = 6.4 Hz), 4.03−4.07 (m, 2H), 2.35 (s,
3H). 13C NMR (CDCl3, 100 MHz): δ 150.29, 149.95, 138.78, 133.13,
131.02, 129.26, 129.00, 66.86, 45.57, 15.32.
2,3,4,5-Tetrahydro-2,8-dimethyl-5-[2-(4-methyl-5-thiazolyl)-
ethyl]-1H-pyrido[4,3-b]indole (24). Caboline (500 mg, 2.5 mmol)
was dissolved in DMSO (5 mL). NaH (120 mg, 60%, 3 mmol) was
added, and the mixture was stirred for 5 min. 4-Methyl-5-vinylthiazole
(2.86 mL, 25 mmol) was added, and the reaction mixture was heated
at 90 °C for 5 h. Reaction was quenched with MeOH (0.5 mL), and
the solvent was evaporated under high vacuum. The residue was
dissolved in DCM (20 mL) and washed with water. The organic phase
was separated and concentrated, and the product was purified by
column chromatography (SiO2, DCM/MeOH, 25:1, 0.1% HOAc, 350
mg, yellow solid, 36%). Compound 24 was obtained as an AcOH salt.
1H NMR (acetone-d6, 400 MHz): δ 8.67 (s, 1H), 7.18−7.22 (m, 2H),
6.93 (d, 1H,J = 8.4 Hz), 4.28 (t, 2H, J = 6.4 Hz), 3.82 (s, 2H), 3.23 (t,
2H, J = 6.4 Hz), 2.92 (t, 2H, J = 6.0 Hz), 2.56−2.62 (m, 5H), 2.38 (s,
3H), 1.96 (s, 3H), 1.91 (s, 3H) . 13C NMR (acetone-d6, 100 MHz): δ
172.71, 150.34,150.75, 135.69, 133.51, 128.69, 128.35, 126.83, 123.21,
118.16, 109.16, 106.11, 52.23, 51.42, 44.69, 44.22, 27.10, 21.84, 21.48,
20.89, 14.43. HRMS calcd for C19H23N3S·CH3CO2H [M + H]
+
326.1691, found 326.1687.
β-Azido-4-methyl-5-thiazoleethanol (25). Epoxide 21 (400 mg,
2.8 mmol) was dissolved in acetonitrile and water (1:1, 10 mL). NaN3
(553 mg, 8.4 mmol) was added. The reaction mixture was refluxed for
1 h. Most of the solvent was removed under reduced pressure. The
residue was dissolved in DCM (20 mL) and washed with water. The
organic phase was separated and concentrated, and the crude product
was purified by column chromatography (SiO2, hexane/ethyl acetate,
1:1, 410 mg, 61%). 1H NMR (CDCl3, 400 MHz): δ 8.71 (s, 1H),
4.98−5.00 (m, 1H), 4.80 (bs, 1H), 3.76−3.87 (m, 2H), 2.49 (s, 3H).
13C NMR (CDCl3, 100 MHz): δ 152.35, 150.67, 126.97, 65.28, 59.85,




1,2,3-triazole (26). Compound 26 was prepared according to the
standard click chemistry procedure described above from 25 and 3-
ethynylpyridine. The crude product was purified by column
chromatography (SiO2, DCM/MeOH, 20:1, 95%).
1H NMR
(CDCl3, 400 MHz): δ 9.05 (s, 1H), 9.01 (s, 1H), 8.80 (s, 1H), 8.52
(d, 1H, J = 3.6 Hz), 8.21 (d, 1H, J = 8.0 Hz), 7.45 (dd, 1H, J = 5.2 Hz,
7.6 Hz), 6.22−6.25 (m, 1H), 4.15−4.20 (m, 1H), 4.04−4.08 (m, 1H),
2.44 (m, 3H). 13C NMR (CDCl3, 100 MHz): δ 153.49, 151.44,
148.90, 146.37, 143.36, 132.42, 126.56, 126.36, 123.96, 121.73, 63.87,




(400 mg, 2.17 mmol) was dissolved in DCM (10 mL) and cooled
in an ice bath. Fuming nitric acid (130 μL) and acetic anhydride (245
μL) were added. The reaction mixture was stirred at 0−4 °C for 4 h.
After dilution with ethyl acetate (20 mL), the reaction mixture was
neutralized by saturated aqueous NaHCO3. The organic phase was
separated and concentrated, and the crude product was purified by
column chromatography (SiO2, hexane/ethyl acetate, 2.5:1, 350 mg,
71%). 1H NMR (CDCl3, 400 MHz): δ 8.79 (s, 1H), 5.24 (t, 1H, J =
2.4 Hz), 4.58 (d, 2H, J = 6.0 Hz), 2.53 (s, 3H). 13C NMR (CDCl3, 100
MHz): δ 152.61, 151.93, 125.14, 73.29, 55.79, 15.33.
β-(4-Methyl-5-thiazolyl)-[4-(3-pyridinyl)-1H-1,2,3-triazole-1-
ethane]-1-nitrate (28) and β-(4-Methyl-5-thiazolyl)-[5-(3-pyr-
idinyl)-1H-1,2,3-triazole-1-ethane]-1-nitrate (29). Compound 27
(260 mg, 1.1 mmol) and 3-ethynylpyridine (234 mg, 2.2 mmol) were
dissolved in toluene (5 mL). The reaction mixture was refluxed for 48
h. Toluene was removed under reduced pressure, and the residue was
purified by column chromatography (SiO2, DCM/MeOH, 20:1). 28
(165 mg, 44%), 1H NMR (CDCl3, 400 MHz): δ 8.98 (s, 1H), 8.82 (s,
1H), 8.59 (d, 1H, J = 3.2 Hz), 8.18 (d, 1H, J = 8.0 Hz), 7.91 (s, 1H),
7.37 (dd, 1H, J = 4.8 Hz, 8.0 Hz), 6.35−6.38 (m, 1H), 5.31−5.36 (m,
1H), 5.09−5.13 (m, 1H), 2.56 (s, 3H). 13C NMR (CDCl3, 100 MHz):
δ153.33, 153.10, 149.63, 147.04, 145.27, 133.11, 126.01, 123.77,
123.58, 119.70, 72.32, 55.41, 15.40. HRMS calcd for C13H12N6O3S [M
+ H]+ 333.0764, found 333.0751. 29 (120 mg, 32%), 1H NMR
(CDCl3, 400 MHz): δ 8.80 (dd, 1H, J = 4.8 Hz, 1.6 Hz), 8.78 (s, 1H),
8.59 (d, 1H, J = 1.6 Hz), 7.80 (s, 1H), 7.64−7.67 (m, 1H), 7.49−7.52
(m, 1H), 5.97−6.01 (m, 1H), 5.44−5.50 (m, 1H), 4.98−5.02 (m, 1H),
2.24 (s, 3H). 13C NMR (CDCl3, 100 MHz): δ 153.83, 151.55, 151.34,
149.41, 136.44, 135.22, 133.71, 124.74, 123.80, 122.30, 72.76, 52.95,




ethanol (30). Nitrate 29 (100 mg, 0.3 mmol) was dissolved in
CH3CN/H2O (2:1, 5 mL). Na2CO3 (300 mg, 3 mmol) and 2-
mercaptoethanol (70 μL, 1 mmol) were added. The reaction mixture
was stirred at room temperature until most of the starting material was
consumed. After dilution with DCM (20 mL), the solution was
washed with H2O and concentrated. The crude product was purified
with column chromatography (DCM/MeOH, 20:1, 81%). 1H NMR
(CDCl3, 400 MHz): δ 8.73 (d, 1H, J = 4.0 Hz), 8.66 (bs, 2H), 7.76−
7.77 (m, 1H), 7.72 (s, 1H), 7.45−7.49 (m, 1H), 5.85−5.88 (m, 1H),
4.65−4.71 (m, 1H), 4.18−4.22 (m, 1H), 2.14 (s, 3H). 13C NMR
(CDCl3, 100 MHz): δ 152.97, 150.91, 150.65, 149.63, 136.91, 135.65,
133.38, 126.45, 123.79, 122.96, 65.62, 58.02, 14.96. HRMS calcd for
C13H13N5OS [M + H]
+ 288.0919, found 288.0916.
β-[4-(3-Pyridyl)phenyl]-4-methyl-5-thiazoleethanol (31). 22c
(350 mg, 1.4 mmol), 3-pyridineboronic acid (270 mg, 2.2 mmol),
Pd(OAc)2 (15 mg), (2-biphenyl)di-tert-butylphosphine (41 mg), and
KF (240 mg, 4.1 mmol) were placed in a flask filled with argon. DMF
(10 mL) was added using a syringe. The mixture was heated at 120 °C
for 1 h. DMF was removed under vacuum, and the residue was diluted
with DCM (50 mL) and washed with water. The crude product was
purified with column chromatography (DCM/MeOH, 20:1, 58%). 1H
NMR (CDCl3, 400 MHz): δ 8.57−8.60 (m, 2H), 8.47 (d, 1H, J = 3.6
Hz), 7.80 (d, 1H, J = 7.6 Hz), 7.47 (d, 2H, J = 8.0 Hz), 7.31−7.37 (d,
3H), 4.50 (t, 1H, J = 6.0 Hz), 4.09−4.18 (m, 2H), 2.38 (s, 3H). 13C
NMR (CDCl3, 100 MHz): δ 150.18, 149.57, 147.96, 147.61, 140.81,
136.27, 136.03, 134.38, 131.51, 128.74, 127.30, 123.57, 66.62, 45.98,




(150 mg, 0.68 mmol) was dissolved in DCM (3 mL) and cooled in
an ice bath. Fuming nitric acid (120 μL) and acetic anhydride (280
μL) were added. The reaction mixture was stirred at 0−4 °C for 4 h.
After dilution with ethyl acetate (20 mL), the reaction mixture was
neutralized by saturated aqueous NaHCO3. The organic phase was
separated and concentrated, and the crude product was purified by
column chromatography (SiO2, hexane/ethyl acetate, 3:1, 110 mg,
61%). 1H NMR (CDCl3, 400 MHz): δ 8.64 (s, 1H), 7.25−7.37 (m,
5H), 4.89−4.94 (m, 1H), 4.80−4.85 (m, 1H), 4.68 (t, 1H, J = 7.2 Hz),
2.40 (s, 3H). 13C NMR (CDCl3, 100 MHz): δ 150.35, 150.21, 138.33,
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130.04, 129.06, 127.86, 127.49, 75.02, 41.34, 15.21. HRMS calcd for
C12H12N2O3S [M + H]
+ 265.0647, found 265.0657.
β-(4-Fluorophenyl)-(4-methyl-5-thiazolyl)ethane-1-nitrate
(32b). Compound 32b was prepared from 22b as described for 32a.
Product was purified by column chromatography (SiO2, hexane/ethyl
acetate, 3:1, 69%). 1H NMR (CDCl3, 400 MHz): δ 8.68 (s, 1H),
7.21−7.27 (m, 2H), 7.03−7.07 (m, 2H), 4.86−4.91 (m, 1H), 4.79−
4.84 (m, 1H), 4.68 (t, 1H, J = 7.2 Hz), 2.40 (s, 3H). 13C NMR
(CDCl3, 100 MHz): δ 163.39, 160.93, 150.56, 150.27, 134.18, 134.14,
129.83, 129.25, 129.17, 116.17, 115.95, 74.85, 40.69, 15.22. HRMS
calcd for C12H11FN2O3S [M + H]
+ 283.0553, found 283.0565.
α-(Phenylmethyl)-(4-methyl-5-thiazolyl)methanenitrate
(33). Compound 33 was prepared from 23a as described for 32a
(86%). 1H NMR (CDCl3, 400 MHz): δ 8.55 (s, 1H), 7.32−7.34 (m,
3H), 7.26−7.28 (m, 2H), 5.88 (t, 1H, J = 7.2 Hz), 3.38−3.44 (m, 1H),
3.24−3.29 (m, 1H), 2.22 (s, 3H). 13C NMR (CDCl3, 100 MHz): δ
150.90, 150.41, 136.15, 129.12, 128.66, 126.22, 124.04, 84.51, 31.27,




(hydroxymethyl)cyclopropane (5.0 g, 48.9 mmol) was dissolved in
DCM (100 mL) and cooled in an ice bath. Fuming nitric acid (2.5
mL) followed by acetic anhydride (5 mL) was added slowly. The
mixture was stirred at 4 °C for 4 h and quenched by aqueous
NaHCO3. The organic phase was separated and washed with water.
The crude product was purified by column chromatography (hexanes/
ethyl acetate, 4:1, 1.2 g, 17%). 1H NMR (acetone-d6, 400 MHz): δ
4.53 (s, 2H), 3.44 (s, 2H), 0.59−0.66 (m, 4H). 13C NMR (acetone-d6,
100 MHz): 78.35, 65.36, 21.35, 8.92.
1-[(Nitrooxy)methyl]cyclopropanecarboxylic Acid (35).
Compound 34 (1.9 g, 12.9 mmol) was dissolved in DCM (100
mL). TEMPO (0.4 g, 2.6 mmol) and PhI(OAc)2 (4.5 g, 14.2 mmol)
were added successively. The reaction mixture was stirred until the
alcohol was no longer detectable by TLC. The reaction mixture was
washed with aqueous Na2S2O3, NaHCO3, and H2O. The organic
phase was separated and concentrated. The residue was purified by
column chromatography (hexanes/ethyl acetate, 2:1). The starting
material was oxidized to an aldehyde as a white solid (1.3 g, 70%). 1H
NMR (acetone-d6, 400 MHz): δ 8.84 (s, 1H), 4.78 (s, 2H), 1.36−1.47
(m, 4H). 13C NMR (acetone-d6, 100 MHz): 199.35, 74.15, 30.35,
12.56. The aldehyde (1.1 g, 7.6 mmol) and 2-methyl-2-butene (8.8
mL) were dissolved in t-BuOH (50 mL). NaH2PO4·H2O (10.0 g) and
NaClO2 (9.0 g) were mixed with H2O (25 mL), and then the mixture
was added to the t-BuOH solution. The reaction mixture was stirred
overnight. Solvent was removed under reduced pressure, and the
residue was diluted with ethyl acetate (200 mL) and washed with
aqueous Na2S2O3 (25 mL), NaHCO3 (25 mL), and H2O (2 × 40
mL). The organic phase was separated, dried over anhydrous MgSO4,
and concentrated. Product was obtained as a white solid (1.1 g, 90%).
1H NMR (acetone-d6, 400 MHz): δ 10.3 (bs, 1H), 4.73 (s, 2H), 1.36−
1.40 (m, 2H), 1.16−1.20 (m, 2H). 13C NMR (acetone-d6, 100 MHz):
174.21, 76.96, 21.58, 14.48.
[1-[(Nitrooxy)methyl]cyclopropanecarboxyl]-[(4-methyl-5-
thiazolyl)phenylmethyl] Ester (36). Compounds 2 (236 mg, 1.15
mmol) and 35 (222 mg, 1.38 mmol) were dissolved in a mixture of
DCM (5 mL) and DIPEA (570 μL). EDCI (330 mg, 1.7 mmol),
HOBt (233 mg, 1.7 mmol), and DMAP (15 mg, 0.13 mmol) were
added. The reaction mixture was stirred overnight and then diluted
with ethyl acetate (50 mL) and washed with water. The organic phase
was separated and concentrated, and the crude product was purified by
column chromatography (SiO2, hexane/ethyl acetate, 2:1, 160 mg,
40%). 1H NMR (CDCl3, 400 MHz): δ 8.66 (s, 1H), 7.29−7.39 (m,
5H), 7.15 (s, 1H), 4.62−4.68 (m, 2H), 2.48 (s, 3H), 1.45−1.52 (m,
2H), 1.06−1.10 (m, 2H). 13C NMR (CDCl3, 100 MHz): δ 170.67,
151.94, 150.66, 138.77, 130.72, 128.76, 128.50, 126.06, 75.06, 71.18,




phenylmethyl] Ester (37). Compound 37 was prepared from 2 and
1-methylcyclopropane-1-carboxylic acid as described for 36 (85%). 1H
NMR (CDCl3, 400 MHz): δ 8.65 (s, 1H), 7.31−7.38 (m, 5H), 7.12 (s,
1H), 2.49 (s, 3H), 1.35 (s, 3H), 1.28−1.32 (m, 2H), 0.72−0.76 (m,
2H). 13C NMR (CDCl3, 100 MHz): δ 174.50, 151.68, 150.40, 139.54,
131.62, 128.70, 128.29, 126.19, 70.16, 19.28, 18.70, 17.03, 17.00,
15.50. HRMS calcd for C16H17NO2S [M + H]
+ 288.1058, found
288.1070.
5-(Methoxyphenylmethyl)-4-methylthiazole (38). To a sol-
ution of 2 (200 mg, 0.87 mmol) in DMF (4 mL) was added NaH (52
mg, 60%, 0.87 mmol). The reaction mixture was stirred at room
temperature for 15 min. CH3I (65 μL, 1 mmol) was added, and the
reaction mixture was stirred for another 3 h. The reaction was
quenched with MeOH (1 mL), and then most of the solvent was
removed under vacuum. The residue was dissolved in ethyl acetate (50
mL) and washed with water. The organic phase was separated and
concentrated. The crude product was purified by column chromatog-
raphy (SiO2, hexane/ethyl acetate, 2:1, 150 mg, 70%).
1H NMR
(acetone-d6, 400 MHz): δ 8.80 (s, 1H), 7.42−7.44 (m, 2H), 7.35−7.39
(m, 2H), 7.27−7.31 (m, 1H), 5.68 (s, 1H), 3.34 (s, 3H), 2.43 (s, 3H).
HRMS calcd for C12H13NOS [M + H]
+ 220.0796, found 220.0792.
5-[[2-(2-Bromoethoxy)ethoxy]phenylmethyl]-4-methylthia-
zole (39). To a solution of 2 (500 mg, 2.4 mmol) in DMF (5 mL) was
added NaH (117 mg, 2.92 mmol). The reaction mixture was stirred at
room temperature for 15 min. Bis(2-bromomethyl) ether (2.2 g, 9.6
mmol) was added, and the reaction mixture was stirred for another 3
h. The reaction was quenched with MeOH (1 mL), and then most of
the solvent was removed. The residue was dissolved in ethyl acetate
(50 mL) and washed with water. The organic phase was separated and
concentrated. The crude product was purified by column chromatog-
raphy (SiO2, hexane/ethyl acetate, 2:1, 740 mg, 86%).
1H NMR
(CDCl3, 300 MHz): δ 8.65 (s, 1H), 7.26−7.39 (m, 5H), 5.75 (s, 1H),
3.81(t, 2H, J = 6.1 Hz), 3.62−3.73 (m, 4H), 3.46 (t, 2H, J = 6.1 Hz),
2.45 (s, 3H). 13C NMR (CDCl3, 100 MHz): δ 151.50, 149.60, 140.83,
133.74, 128.60, 128.09, 126.58, 77.31, 71.25, 70.65, 68.36, 30.45,
15.57.
1-Nitrooxy-2-[2-[(4-methyl-5-thiazolyl)phenylmethoxy]-
ethoxy]ethane (40). Silver nitrate (2.0 g, 11.8 mmol) was added to a
solution of 39 (1.1 g, 3.1 mmol) in CH3CN (15 mL). The reaction
was refluxed for 2 h and then diluted with ethyl acetate (50 mL). After
filtration and concentration, the crude product was purified by column
chromatography (SiO2, hexane/ethyl acetate, 1.5:1, 720 mg, 69%).
1H
NMR (CDCl3, 400 MHz): δ 8.62 (s, 1H), 7.26−7.38 (m, 5H), 4.59 (t,
2H, J = 4.4 Hz), 3.77 (t, 2H, J = 4.4 Hz), 3.67−3.69 (m, 2H), 3.62−
3.64 (m, 2H), 2.45 (s, 3H). 13C NMR (CDCl3, 100 MHz): δ 151.40,
149.46, 140.63, 133.55, 128.49, 127.99, 126.39, 77.22, 72.03, 70.69,




(41). To a solution of 40 (70 mg, 0.21 mmol) in THF (5 mL) was
added LiAlH4 (35 mg, 0.85 mmol). The mixture was refluxed for 1 h
and then quenched with methanol. Solvent was removed under
reduced pressure, and the residue was diluted with ethyl acetate and
washed with water. The crude product was purified by column
chromatography (SiO2, hexane/acetone, 2:1, 25 mg, 41%).
1H NMR
(CDCl3, 400 MHz): δ 8.64 (s, 1H), 7.29−7.38 (m, 5H), 5.70 (s, 1H),
3.71−3.74 (m, 4H), 3.60−3.66 (m, 4H), 2.45 (s, 3H). 13C NMR
(CDCl3, 100 MHz): δ 151.60, 149.56, 140.71, 133.66, 128.65, 128.16,
126.52, 72.38, 70.37, 68.49, 61.80, 15.52. HRMS calcd for
C15H19NO3S [M + H]
+ 294.1164, found 294.1169.
N-[(4-Methyl-5-thiazolyl)phenylmethyl]-[1-[(nitrooxy)-
methyl]cyclopropyl]methyl Carbamate (42). Compound 4 (160
mg, 0.78 mmol) and triphosgene (297 mg, 1.0 mmol) were dissolved
in ethyl acetate (10 mL) and refluxed for 2 h. Solvent was removed.
The residue was redissolved in a mixture of THF (5 mL) and NEt3
(0.25 mL, 1.8 mmol), and 34 (147 mg, 1 mmol) was added. The
reaction mixture was stirred at 40 °C for 1 h. Solvent was removed,
and the product was purified by column chromatography (SiO2,
hexane/ethyl acetate, 2:1, 150 mg, 51%). 1H NMR (CDCl3, 400
MHz): δ 8.55 (s, 1H), 7.27−7.36 (m, 5H), 6.19 (s, 1H), 5.98 (s, 1H),
4.35 (s, 2H), 3.98 (s, 2H), 2.39 (s, 3H), 0.67−0.71 (m, 4H). 13C NMR
(CDCl3, 100 MHz): δ 155.21, 150.51, 149.68, 140.32, 133.53, 128.69,
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127.93, 126.39, 77.06, 68.31, 51.97, 30.68, 18.33, 15.08, 9.41. HRMS
calcd for C17H19N3O5S [M + H]
+ 378.1124, found 378.1114.
N-[(4-Methyl-5-thiazolyl)phenylmethyl]-[4-(nitrooxy)butyl]
Carbamate (43). Compound 43 was prepared from 4 and 4-
nitrooxybutan-1-ol90 using the same procedure described for 42.
Product was purified by column chromatography (SiO2, hexane/ethyl
acetate, 2:1, 65%). 1H NMR (CDCl3, 400 MHz): δ 8.60 (s, 1H),
7.27−7.38 (m, 5H), 6.19 (bs, 1H), 5.45 (bs, 1H), 4.45 (bs, 2H), 4.13
(t, 2H, J = 5.6 Hz), 2.41 (s, 3H), 1.60−1.80 (m, 4H). 13C NMR
(CDCl3, 100 MHz): δ 155.35, 150.46, 149.51, 140.31, 133.60, 128.60,
127.83, 126.35, 72.40, 64.10, 51.81, 25.01, 23.18, 14.98. HRMS calcd
for C16H19N3O5S [M + H]
+ 366.1124, found 366.1117.
N-[(4-Methyl-5-thiazolyl)phenylmethyl]-1-[(nitrooxy)-
methyl]cyclopropanecarboxamide (44). Compound 44 was
prepared from 4 and 35 as described for 36. The crude product was
purified by column chromatography (SiO2, hexane/ethyl acetate, 1:1,
49%). 1H NMR (CDCl3, 300 MHz): δ 8.59 (s, 1H), 7.23−7.38 (m,
5H), 6.61 (d, 1H, J = 7.2 Hz), 6.45 (d, 1H, J = 7.3 Hz), 4.58 (s, 2H),
2.39 (s, 3H), 1.35−1.39 (m, 2H), 0.94−0.97 (m, 2H). 13C NMR
(CDCl3, 100 MHz): δ 169.97, 150.58, 150.04, 139.98, 133.04, 128.97,
128.18, 126.50, 76.03, 50.59, 22.68, 15.26, 13.74, 13.66. HRMS calcd
for C16H17N3O4S [M + H]
+ 348.1018, found 348.1008.
Stability of NO-Chimera in Neutral Phosphate Buffer. Stock
solutions of 36, 37, and 42 were made in DMSO. 36 or 37 (10 μM)
and 5i (internal standard, 10 μM) were dissolved in phosphate buffer
(100 mM, pH 7.4), and the final concentration of DMSO was 2% (v/
v). The solution was kept in the autosampler of the HPLC instrument
at room temperature, and an aliquot (50 μL) was injected into HPLC
column. Injection occurred about every 7 min for 36 and 67 min for
37 because of the different stability of the two compounds. HPLC
analysis was performed using a Shimadzu UFLC instrument with UV
absorbance detection at 254 nm. Separation of parent compound,
hydrolysis product (compound 2), and internal standard (IS) was
achieved using a Hypersil BDS C18 column (2.1 mm × 30 mm, 3
μm). The composition of the HPLC mobile phase was a mixture of
water with 10% methanol, 0.1% formic acid (solution A), and
acetonitrile with 0.1% formic acid (solution B). The mobile phase was
initially composed of solvent A/solvent B (90:10), held for 1 min, and
then a linear gradient of solution B from 10% to 95% over the next 3
min. The solvent was held at 95% of solution B over 1 min, and the
column was finally balanced using 10% solvent B for 1.5 min. Flow rate
was 0.5 mL/min. Peak area ratio of parent compound vs internal
standard was calculated at each time point and divided by the time
zero value to give the percentage of compound remaining.
To detect the decomposition products of 42, the compound (100
μM) was dissolved in phosphate buffer (100 mM, pH 7.4). The final
concentration of DMSO was 2% (v/v). The sample was placed in the
dark at room temperature for 48 h. An aliquot (10 μL) of the sample
was analyzed using an Agilent 6310 ion trap mass spectrometer
(Agilent Technologies, Santa Clara, CA) equipped with Agilent 1100
HPLC system and electrospray ionization (ESI) source operated in
positive mode. HPLC was performed using an Agilent Zorbax Bonus
reverse phase C18 column (3.0 mm × 150 mm, 3.5 μm) with UV
absorbance detection at 254 nm. The composition of the HPLC
mobile phase was a mixture of water with 10% methanol, 0.1% formic
acid (solution A), and acetonitrile with 0.1% formic acid (solution B).
The mobile phase was initially composed of solvent A/solvent B
(90:10), held for 1 min, and then a linear gradient of solution B from
10% to 80% over 17 min, 0.5 min gradient of solution B from 80% to
95% and held for 5 min. Flow rate was set at 0.5 mL/min.
Animals.Male C57BL/6 mice aged 8−10 weeks (20−25 g, Charles
River Laboratories, IL) were used for step-through passive avoidance
(STPA) task and brain bioavailability assay. Sprague−Dawley rat
(gestational days 17−18, Charles River Laboratories, IL) were used for
the primary neuronal cultures. Animals were housed at the BRL
(biological resources laboratories) animal facility at the University of
Illinois at Chicago (UIC). The animals were kept under standard
laboratory conditions with free access to dry food and water but no
nesting materials (Nestlets) supplied (not enriched environment).
Regular light−dark cycle with at least 12 h of light was maintained
throughout the housing in the facility. Animals were acclimated for at
least 1 week in BRL before running any experiment. Also, 1−2 h prior
to each testing, mice were habituated to the animal study room in the
facility. All protocols using live animals were reviewed and approved by
Institutional Animal Care and Use Committee (IACUC) at UIC
(Animal Care Committee). Injection volumes were adjusted based on
the animal weight (0.1 mL/25 g mouse).
Double transgenic APP/PS1 mice expressing both the human APP
(K670M:N671L) and PS1 (M146L) (line 6.2) mutations were used
for the LTP study. They were obtained by crossing APP with PS1
animals.38 The animals were maintained on a 12 h light/dark cycle
(with light onset at 6:00 a.m.) in temperature- and humidity-controlled
rooms of the Columbia University Animal Facility. Food and water
were available ad libitum.
Primary Neuronal Cultures. Primary cultures of rat cortical
neurons were prepared as described.91 Briefly, brains were removed
from embryonic day 17 Sprague−Dawley rat embryos, cortices were
dissected, and meninges were removed. Neurons were mechanically
dissociated in basal medium Eagle 1× containing glucose (33 mM),
glutamine (2 mM), 10% horse serum, and 10% FBS and then plated at
3 × 105 cells/cm2 in poly-L-lysine-precoated plates. The medium was
replaced 24 h later with serum-free neurobasal medium (NBM)
supplemented with 0.5 mmol/L-glutamine and 2% complete B27
supplement. Four days later, 50% of the medium was replaced with
fresh NBM. Neurons were used for OGD or NMDA cytotoxicity
experiments after being grown for 8−10 days in NBM.
Primary Neurons Subject to Transient OGD Followed by
Reoxygenation. Primary cortical cultured neurons were subjected to
a transient OGD as described.92 On days 8−10 of culture, cultured
neurons were placed in a humidified 37 °C incubator (95% N2, 5%
CO2) and the culture medium was replaced with deoxygenated,
glucose-free balanced salt solution, pH 7.4, containing the following
(in mM): NaCl 116, CaCl2 1.8, MgSO4 0.8, KCl 5.4, NaH2PO4 1,
NaHCO3 14.7, and HEPES 10. Following 2 h of OGD incubation,
OGD was ended by replacing OGD medium with testing compound
conditioned fresh NBM (supplemented with 0.5 mmol/L-glutamine
and B27 without antioxidants). Cultures were returned to the
normoxic 37 °C incubator (5% CO2) for 24 h prior to evaluation of
cell viability and neuronal death by MTT and LDH assays. The test
compounds (50 μM) were present during the 2 h OGD and 24 h
reoxygenation.
NMDA and Glutamate Induced Cytotoxicity in Primary
Neurons. Primary cortical cultured neurons were subjected to NMDA
induced cytotoxicity as described.93,94 On day 11 of culture, primary
neurons were preincubated with testing compounds (50 μM) for 30
min in neurobasal culture mudium and were exposed to NMDA (100
μM) in HEPES-buffered salt solution containing the following (in
mM): NaCl 20, KCl 5.4, MgCl2 0.8, CaCl2 1.8, glucose 15, and
HEPES 20 (pH 7.4). Twenty-four hours later, cell viability and
neuronal death were evaluated by MTT and LDH assays. The testing
compounds (50 μM) were presented during the preincubation and 24
h chronic NMDA cytotoxicity. MTT assay for cell viability and LDH
assay of cell death were performed as described previously.95
To probe the mechanism of neuroprotection elicited by MZ
derivatives, after 10−11 DIV (days in vitro), picrotoxin (100 μM) was
added to primary neuronal cultures 1 h before glutamate (100 μM)
insult. One hour after glutamate addition, MZ derivatives or muscimol
were supplied at a final concentration of 50 μM. After incubation for
24 h, final cell survival was assayed using MTT. For comparison,
picrotoxin treatment was omitted in another experiment.
LTP Measurement. Hippocampal slice preparation was performed
as described.38 Briefly, APP/PS1 trangenic mice were decapitated and
their hippocampi were quickly removed. Transverse hippocampal
slices (400 μm) were cut and transferred to an interface chamber,
where they were maintained at 29 °C. They were perfused (1−3 mL/
min) with saline solution (124.0 mM NaCl/4.4 mM KCl/1.0 mM
Na2HPO4/25.0 mM NaHCO3/2.0 mM CaCl2/2.0 mM MgSO4/10
mM glucose) continuously bubbled with 95% O2 and 5% CO2. Slices
were maintained at 29 °C for 90 min before recording. The CA1
region of the hippocampus field excitatory postsynaptic potentials
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(fEPSPs) were recorded by placing both the stimulating and the
recording electrodes in CA1 stratum radiatum. A 15 min baseline was
recorded every minute at an intensity that evokes a response of
approximately 35% of the maximum evoked response. LTP was
induced using θ-burst stimulation at 20 min. Responses were recorded
for 1 h after tetanization.
Step-Through Passive Avoidance (STPA) Task. The STPA
apparatus consists of a two-compartment acrylic box with an
illuminated side (15 cm × 12 cm × 12 cm) connected to a dark
side (15 cm × 12 cm × 12 cm) by a vertical door. The dark side is
equipped with an electric grid floor. Animals was habituated to
translocating to the dark from the light side until latency of entering
the dark side for each animal is <30 s. During training, animals
received an aversive electrical shock (0.5 mA, 2 s), triggered by entry
to the dark compartment, until the latency of entering the dark side
reaches 300 s. To test procognitive activity of NO-chimeras,
scopolamine (1.0 mg/kg, ip) was given 30 min before training and
drug (4.5 μmol/kg, ip) was administered 20 min before training. At 24
h after training, the animals were again individually placed in the light
compartment and the latency to enter the dark comparment, without
shock stimulus, was recorded. Statistical analysis of the latency data
was performed with one-way ANOVA followed by Bonferroni multiple
comparison test.
Brain Bioavailability of NO-Chimeras. Mice were injected (ip)
with drug at a dosage that was equimolar with 1 (4.5 μmol/kg, ip).
Four mice were used for the injection of each drug. Brain tissues were
collected 20 min after ip injection. Analytes were extracted as follows:
to a mixture of blank brain tissue (100 mg) and cold acetonitrile/
MeOH (1:1, 600 μL), internal standard (400 ng/mL, 10 μL) in
acetonitrile/MeOH (1:1) was added. Brain tissue was homogenized
manually using a disposable pestle, vortexed, and then centrifuged at 4
°C, 13 000 rpm for 15 min. The supernatant was transferred to
another vial. The remaining pellet was washed and extracted with cold
acetonitrile/MeOH (300 μL,1:1 v/v) and centrifuged as described
above. Supernatants were combined and stored at −20 °C for 1 h,
allowing further protein precipitation. The clear supernatant from
centrifugation was collected and concentrated using a flow of N2. The
residue was reconstituted with solvent (200 μL, H2O/MeOH/
acetonitrile, 50/25/25, v/v), vortexed, centrifuged, and analyzed
using LC−MS/MS. To construct standard curves, working solutions in
MeOH/acetonitrile/H2O (0.5:0.5:1) containing NO-chimera and
corresponding hydroxyl compound at different concentrations were
prepared. Concentrations of working solutions were 2000, 1000, 500,
200, 80, 40, 20 ng/mL. To a mixture of blank brain tissue (100 mg)
and cold acetonitrile/MeOH (1:1, 600 μL) were added each analyte
working solution (10 μL) and internal standard (400 ng/mL, 10 μL).
Calibration samples were extracted as described above, and the final
concentrations of analytes after reconstitution were 100, 50, 25, 10, 4,
2, 1 ng/mL. The final concentration of IS was 20 ng/mL.
All LC−MS/MS measurements were carried out using the positive
mode electrospray ionization method on an API 3000 (Applied
Biosystem, Foster City, CA) triple quadrupole mass spectrometer
attached to an Agilent 1200 HPLC (Agilent Technologies) instru-
ment. MRM transitions for the detection of analytes and internal
standards are described in Table 2. HPLC was performed with a
Waters XBridge C18 column (3.5 μm, 3 mm × 100 mm). Flow rate
was set at 0.35 mL/min. The composition of the HPLC mobile phase
was a mixture of water with 10% methanol, 0.1% formic acid (solution
A), and acetonitrile with 0.1% formic acid (solution B). To analyze
32a and 22a, the mobile phase was initially composed of solvent A/
solvent B (90:10), held for 1 min, and a linear gradient of solution B
from 10% to 60% over the next 1 min. The composition of B was then
increased to 99% in 13 min. The solvent was held at 99% of solution B
over 5 min, and the column was finally balanced using 10% solvent B
for 5 min. To analyze 26 and 28, the mobile phase was initially
composed of solvent A/solvent B (95:5), held for 1 min, and a linear
gradient of solution B from 10% to 60% over next 1 min. Composition
of B was then increased to 99% in 11 min. The solvent was held at
99% of solution B over 5 min, and the column was finally balanced
using 5% solvent B for 5 min.
Statistical Analyses. For all experiments, data were expressed as
the mean ± SEM. LTP results were analyzed with two-way ANOVA.
STPA results were analyzed with one-way ANOVA followed by
Bonferroni multiple comparison test. The level of significance was set
for p < 0.05.
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